On Tuesday, WisdomTree Investments, Inc. (NASDAQ:WETF)’s shares inclined 0.78% to $21.97.
WisdomTree Investments, Inc. (WETF) declared the hire of Kurt MacAlpine as Executive Vice President-Head of Global Distribution. In a newly created role, Mr. MacAlpine will oversee WisdomTree`s ETP sales and distribution initiatives globally and join WisdomTree`s executive administration team. He joins WisdomTree from McKinsey & Company where he was a Partner and Leader of the North American Asset Administration practice.
As a Partner at McKinsey & Company, Kurt managed global consulting teams in the asset administration and wealth administration industries on topics related to distribution, marketing, product development, international expansion, strategy and M&A. He has extensive experience working with domestic and foreign firms in North America, Asia and Europe. Kurt was also a member of McKinsey`s Global Asset and Wealth Administration Operating Committee.
WisdomTree Investments, Inc., through its auxiliaries, operates as an exchange-traded funds (ETFs) sponsor and asset manager. It offers ETFs in equities, currency, fixed income, and alternatives asset classes.
CorMedix Inc. (NYSEMKT:CRMD)’s shares dropped -4.44% to $3.87.
CorMedix Inc. (CRMD) declared that the U.S. Food and Drug Administration (FDA) has offered positive feedback regarding a second pivotal clinical trial protocol. The new Phase 3 protocol is designed to assess the use of Neutrolin® as a catheter lock solution in oncology patients who require total parenteral nutrition (TPN) to support filing of a New Drug Application with the FDA. The comments offered by the FDA should enhance the quality of the projected study.
Neutrolin has shown antimicrobial activity against many of the pathogens that result in catheter related bloodstream infections in the oncology community. Infections pose a noteworthyrisk for oncology patients, many of whom require the long-term use of central venous catheters. CorMedix hopes that the use of Neutrolin in this susceptible population will assist address a critical unmet medical need. Formerly, the FDA reviewed the pivotal Phase 3 clinical trial protocol to evaluate the use of Neutrolin in hemodialysis patients, and preparations are underway to initiate the trial subject to identification of funding or planned partnering.
CorMedix Inc., a pharmaceutical company, intends to in-license, develop, and commercialize therapeutic products for the prevention and treatment of cardiac, renal, and infectious diseases. The company markets Neutrolin, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, and central venous catheters used for vascular access in hemodialysis patients.
At the end of Tuesday’s trade, NextEra Energy Inc (NYSE:NEE)‘s shares dipped -0.14% to $98.03.
Silagy has been with FPL and its parent company NextEra Energy Inc (NEE), Florida Power & Light Company (FPL) declared that its President and Chief Executive Officer Eric Silagy has been designated to the U.S. Chamber of Commerce Board of Directors for a two-year term. Silagy joins an influential group of 100 business leaders who champion the interests of more than 3 million businesses of all sizes, sectors and regions.
NextEra Energy, Inc., through its auxiliaries, generates, transmits, and distributes electric energy in the United States and Canada. The company generates electricity from gas, oil, solar, coal, petroleum coke, nuclear, and wind sources. As of December 31, 2014, it served about 9 million people through about 4.7 million customer accounts in the east and lower west coasts of Florida.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.